Year All20242023202220212020201920182017201620152014 Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call October 23, 2024 Corcept Therapeutics Announces Second Quarter Financial Results and Provides Corporate Update July 29, 2024 Corcept Therapeutics to Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference Call July 22, 2024 Corcept Announces Presentation of Results From Prevalence Phase of CATALYST Clinical Trial at American Diabetes Association’s Scientific Sessions June 24, 2024 Corcept Therapeutics Announces Presentations of Results of Pivotal Phase 3 GRACE Trial Evaluating Relacorilant in Patients with Hypercortisolism (Cushing’s Syndrome) June 3, 2024 Corcept Announces Primary Endpoint Met in Pivotal Phase 3 GRACE Trial of Relacorilant in Patients With Hypercortisolism (Cushing’s Syndrome) May 28, 2024 Corcept Therapeutics Announces First Quarter Financial Results and Provides Corporate Update May 1, 2024 Corcept Completes Enrollment in Phase 4 CATALYST Trial April 29, 2024 Corcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference Call April 24, 2024 Corcept Announces Positive Results From Open-Label Portion of Pivotal Phase 3 GRACE Trial in Patients With Cushing’s Syndrome April 22, 2024
Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call October 23, 2024
Corcept Therapeutics Announces Second Quarter Financial Results and Provides Corporate Update July 29, 2024
Corcept Therapeutics to Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference Call July 22, 2024
Corcept Announces Presentation of Results From Prevalence Phase of CATALYST Clinical Trial at American Diabetes Association’s Scientific Sessions June 24, 2024
Corcept Therapeutics Announces Presentations of Results of Pivotal Phase 3 GRACE Trial Evaluating Relacorilant in Patients with Hypercortisolism (Cushing’s Syndrome) June 3, 2024
Corcept Announces Primary Endpoint Met in Pivotal Phase 3 GRACE Trial of Relacorilant in Patients With Hypercortisolism (Cushing’s Syndrome) May 28, 2024
Corcept Therapeutics Announces First Quarter Financial Results and Provides Corporate Update May 1, 2024
Corcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference Call April 24, 2024
Corcept Announces Positive Results From Open-Label Portion of Pivotal Phase 3 GRACE Trial in Patients With Cushing’s Syndrome April 22, 2024